

1 An optimal 1H-MRS technique at 7T: Proof-of-principle
2 in Chronic Multiple Sclerosis and Neuromyelitis Optica
3 Brain Lesions and Normal Appearing Brain Tissue.

4
5 George Tackley [1,2,*,§], Yazhuo Kong [3,4,*], Rachel Minne [5], Silvia Messina [7], Anderson
6 Winkler[1,8], Ana Cavey [7], Rosie Everett [7], Gabriele C DeLuca [7], Andrew Weir [7], Matthew
7 Craner [7], Irene Tracey [1], Jacqueline Palace [7], Charlotte J Stagg[1,9,**] and Uzay Emir[1,5,6,**]

8
9 ¹ Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical
10 Neurosciences, University of Oxford, Oxford, OX3 9DU, UK

11 ² Cardiff University Brain Research Imaging Centre (CUBRIC), Cardiff University, CF24 4HQ, UK

12 ³ CAS Key Laboratory of Behavioural Science, Institute of Psychology, Chinese Academy of Sciences,
13 Beijing 100101, China

14 ⁴ Department of Psychology, University of Chinese Academy of Sciences, Beijing 100049, China

15 ⁵ School of Health Sciences, Purdue University, 550 Stadium Mall Drive, West Lafayette, IN 47907,
16 (765) 494-1419, USA

17 ⁶ Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, United States

18 ⁷ Division of Clinical Neurology, Nuffield Department of Clinical Neurosciences, University of Oxford,
19 Oxford, OX3 9DU, UK

20 ⁸ National Institute of Mental Health (NIMH), National Institutes of Health (NIH), Bethesda, MD, USA

21 ⁹ MRC Brain Network Dynamics Unit, University of Oxford, Oxford, OX1 3TH, UK

22
23 § To whom correspondence should be addressed:

24 Dr George Tackley, CUBRIC, Cardiff, Wales, tackleyg@cardiff.ac.uk

25

26 * Joint first authors

27 ** Joint last authors

28

29 Abstract

30 Magnetic Resonance Spectroscopy (MRS) allows for the non-invasive quantification of
31 neurochemicals and has the potential to differentiate between the pathologically distinct diseases,
32 multiple sclerosis (MS) and AQP4Ab-positive neuromyelitis optica spectrum disorder (AQP4Ab-
33 NMOSD). In this study we characterised the metabolite profiles of brain lesions in 11 MS and 4
34 AQP4Ab-NMOSD patients using an optimised MRS methodology at ultra-high field strength (7T)
35 incorporating correction for T2 water relaxation differences between lesioned and normal tissue.

36

37 MS metabolite results were in keeping with the existing literature: total NAA was lower in lesions
38 compared to normal appearing brain white matter (NAWM) with reciprocal findings for Inositol. An
39 unexpected subtlety revealed by our technique was that total NAA differences were driven by NAA-
40 glutamate (NAAG), a ubiquitous CNS molecule with functions quite distinct from NAA though
41 commonly quantified together with NAA in MRS studies as total NAA. Surprisingly, AQP4Ab-NMOSD
42 showed no significant differences for total NAA, NAA, NAAG or Inositol between lesion and NAWM
43 sites, nor were there any differences between MS and AQP4Ab-NMOSD for *a priori* hypotheses.
44 Post-hoc testing did however reveal greater total NAA in MS compared to AQP4Ab-NMOSD NAWM.
45 Post-hoc testing also revealed a significant correlation between NAWM Ins:NAA and disability (as
46 measured by EDSS) for disease groups combined, driven by the AP4Ab-NMOSD group.

47

48 Utilising an optimised MRS methodology, our study highlights some under-explored subtleties in
49 MRS profiles, such as the absence of Inositol concentration differences in AQP4Ab-NMOSD brain
50 lesions versus NAWM and the important influence of NAAG differences between lesions and normal
51 appearing white matter in MS.

52

53 Abbreviations

- 54 Asc, ascorbate
- 55 Cr, creatine
- 56 GABA, gamma aminobutyric acid
- 57 Glc+Tau, glucose and taurine
- 58 Gln, glutamine
- 59 Glu, glutamate
- 60 Glx, Gln + Glu
- 61 GPC, glycerophosphocholine
- 62 GSH, glutathione
- 63 Ins / Inositol, *myo*-inositol
- 64 NAA, N-acetylaspartate (i.e. *not* including NAAG)
- 65 NAAG, N-acetylaspartylglutamate
- 66 PCr, phosphocreatine
- 67 PE, phosphorylethanolamine
- 68 Tau, taurine
- 69 tCho, total choline (GPC + Cho)
- 70 tCr, total creatine (Cr + PCr)
- 71 tNAA, total N-acetylaspartate (NAA + NAAG)
- 72
- 73
- 74
- 75

76 1. Introduction

77 Magnetic Resonance Spectroscopy (MRS) allows for the non-invasive quantification of
78 neurochemicals, and therefore has the potential to differentiate between pathologically distinct
79 diseases. This is perhaps especially important in circumstances where clinical syndromes may
80 overlap but treatment strategies are distinct. In particular, there is interest in utilising MRS to
81 differentiate the primary astrocytopathy Aquaporin-4 Antibody positive Neuromyelitis Optica
82 Spectrum Disorders (AQP4Ab-NMOSD) (Fujihara, 2011) from the clinically similar but pathologically
83 distinct disorder, Multiple Sclerosis (MS), which is believed to be a chronic inflammatory
84 demyelinating disorder with secondary neurodegeneration (Lucchinetti et al., 2014; Wingerchuk et
85 al., 2015). In addition, where MRS metrics prove sensitive to the underlying pathology in a disease
86 state, they can inform our understanding of that pathology, and potentially be developed as
87 biomarkers for future pharmacological studies.

88

89 MRS studies in MS consistently report a core pattern of findings. Compared to healthy control brain
90 tissue, lesions of all ages show reduced total N-acetyl aspartate (tNAA) likely reflecting decreased
91 neuronal mitochondrial activity, and raised Inositol-containing compounds (Ins), commonly taken to
92 reflect glial activity (Brex et al., 2000; Ciccarelli et al., 2013; Miller et al., 2003). A similar pattern of
93 changes is found in MS normal appearing white matter (NAWM) versus healthy controls, though to a
94 smaller degree (De Stefano et al., 2007; Fernando et al., 2004; Helms et al., 2000; Miller et al., 2003).
95 In addition to changes in specific metabolites, the relative concentrations of some MRS metabolites
96 have also been correlated with clinical metrics. The relative concentration of Inositol and NAA
97 (without NAAG) in NAWM (Ins:NAA), which provides an insight into the relative activity of glia and
98 neurons within a given region, has been shown to predict disease progression in MS. It has been
99 hypothesised to be a sensitive index that encapsulates both the damaging immune-mediated gliosis
100 (increase in Inositol) and the disabling neurodegenerative axonal loss (reduction in NAA) that are

101 known features of MS pathology, and it has been shown to predict disease progression (Llufriu et al.,
102 2014; Miller DH, 2014).

103

104 In patients with AQP4Ab-NMOSD, there is little or no evidence for a difference in either tNAA (i.e.
105 NAA + NAAG) or Inositol in normal appearing white matter compared to controls (Aboul-Enein et al.,
106 2010; Bichuetti et al., 2008; Kremer et al., 2015), raising the possibility that Inositol and tNAA may be
107 sensitive discriminators between AQP4Ab-NMOSD and MS. However, no studies to date have
108 studied MRS-quantified neurochemicals within AQP4Ab-NMOSD lesions in the brain. A single study
109 has examined MRS-derived neurochemical profiles in AQP4Ab-NMOSD lesions within the spinal cord
110 and demonstrated significantly lower Inositol in AQP4Ab-NMOSD lesions compared with both MS
111 cord lesions and healthy controls (Ciccarelli et al., 2013), consistent with previously observed
112 astrocyte damage and loss in AQP4Ab-NMOSD lesions. The authors also demonstrated, in line with
113 existing literature, a substantial decrease in tNAA in MS lesions compared with healthy controls, but
114 no significant difference in tNAA between AQP4Ab-NMOSD lesions and either MS lesions or controls.

115

116 Here, we wished to see whether MRS could distinguish between AQP4Ab-NMOSD and MS lesions in
117 the brain. However, there are a number of technical difficulties in performing MRS in the context of
118 neurological disease that are important to overcome in order to accurately address this question. In
119 particular, lesioned tissue has a longer T2 than non-lesioned tissue, due to its increased water
120 content (Zimmerman et al., 1986), which, if not compensated for (e.g. by using a short TE and T2*
121 measurement), will directly influence metabolite quantification. In addition, it is important to fully
122 separate neurochemicals with highly similar spectral resonances but disparate physiological
123 functions, for example NAA and the closely chemically related, but functionally distinct, NAA-
124 glutamate (NAAG), often combined in the MRS metric tNAA. This is particularly important in the
125 context of neurodegeneration, as NAA reflects neuronal mitochondrial function, whereas NAAG acts

126 as a neuromodulator (Baslow, 2000; Birken and Oldendorf, 1989; Neale et al., 2000). It is therefore
127 difficult to clearly interpret changes in the tNAA metric in terms of the underlying pathology.

128

129 We therefore exploited recent advances in MRS methodology to study pathological differences
130 between AQP4Ab-NMOSD and MS lesions. We used an ultra-high field (7T) scanner, to allow
131 separation between NAA and NAAG, something not easily achievable at 3T, and modelled multiple
132 water T2-relaxation times to compensate for lesion-related effects on metabolite quantification
133 (Helms, 2001), approaches that have been little used in this context before now.

134

135 We wished to test the hypotheses that (1) Inositol would be higher in MS brain lesions than AQP4Ab-
136 NMOSD brain lesions, reflecting the likely increased astrocytic damage in AQP4Ab-NMOSD
137 compared to the reciprocal astrogliosis found in MS lesions, and (2) that NAA (tNAA, NAA & NAAG)
138 would be higher in the normal appearing white matter in AQP4Ab-NMOSD patients compared with
139 MS patients, in line with the relative lack of extra-lesional neurodegeneration in AQP4Ab-NMOSD
140 (Matthews et al., 2015). Within diseases we also hypothesised that (3) NAA (tNAA, NAA & NAAG)
141 would be greater in NAWM than lesion sites in line with expected neuronal loss in lesions, and that
142 (4) inositol would be differentially *greater* in MS brain lesion versus NAWM sites and *lower* in
143 AQP4Ab-NMOSD lesion versus NAWM sites reflecting the contrasting gliotic and astrocytopathic
144 nature of lesions in these two conditions.

145 2. Methods

146 *2.1 Subjects*

147 Eleven patients with clinically diagnosed relapsing-remitting multiple sclerosis (RRMS) and four
148 patients with AQP4Ab-NMOSD gave their written informed consent to participate in the study,
149 under local ethics board approval (Oxfordshire REC A 10/H0604/99; Berkshire REC 13/SC/0238). In

150 addition to MR scanning, patients underwent a short clinical consultation and neurological
151 examination including EDSS scoring. Current medications were recorded. Minimum lesion age was
152 calculated as the time from the oldest clinical brain MRI to contain the targeted lesion.

153 *2.2 MR Acquisition*

154 MR was performed on a 7T Siemens MAGNETOM system (Siemens, Erlangen, Germany) equipped
155 with a Nova Medical 32 channel receive array head coil. Two MRS volumes-of-interest (VOIs) were
156 acquired per subject: one targeting a chronic, T2-hyperintense, T1-hypointense white matter lesion
157 (>3 months old, confirmed on historical clinical MRIs) and another centred on a contralateral area of
158 normal appearing white matter (NAWM; a majority white-matter voxel, avoiding as much grey
159 matter and cerebrospinal fluid as possible), positioned as close as possible to contralateral
160 reflection-symmetrical with the lesion voxel. The spectroscopy voxel volume was 15 x 15 x 15mm.

161

162 Spectroscopy voxels were manually positioned by reference to a 1mm isotropic T2-weighted fluid-
163 attenuated inversion recovery (FLAIR) image (1mm isotropic, TR = 5s, TE = 272 ms, TI = 1.8 sec) (See
164 Supplemental Figure 1 for individual voxel locations). First- and second-order shims were first
165 adjusted by gradient-echo shimming (Shah et al., 2009). The second step involved only fine
166 adjustment of first order shims using FASTMAP (Gruetter and Tkáč, 2000). Spectra were acquired
167 using a Stimulated Echo Acquisition Mode (STEAM) pulse sequence (TE=11ms, TR=5s, number of
168 transients=64) with variable power radiofrequency pulses with optimized relaxation delay (VAPOR),
169 water suppression and outer volume saturation (Emir et al., 2012). Unsuppressed water spectra
170 acquired from the same voxel were used to remove residual eddy current effects and to reconstruct
171 the phased array spectra.

172

173 Finally, fully relaxed unsuppressed water signals were acquired at TEs ranging from 11 to 4000ms
174 (TR=15s) to estimate the cerebrospinal fluid (CSF) contribution to each VOI (see below). A whole-

175 brain T1-MPRAGE (1mm isotropic, TR = 2.2s, TE = 282ms) was also acquired to evaluate T1 hypo-
176 intensity in lesions.

177 *2.3 MRS Analysis*

178 Absolute metabolite concentrations were obtained relative to an unsuppressed water spectrum
179 acquired from the same VOI. The transverse relaxation times (T2) of tissue water and percent CSF
180 contribution to the VOI were obtained by fitting the integrals of the unsuppressed water spectra
181 acquired in each VOI at different TE values with a biexponential fit (Piechnik et al., 2009), with the T2
182 of CSF fixed at 640ms and three free parameters: T2 of tissue water, amplitude of tissue water, and
183 amplitude of CSF water.

184

185 LCModel (Provencher, 2001) was used for spectral analysis and quantification. Single-subject
186 metabolites were only retained if the Cramér-Rao lower bounds (CRLBs) estimated error of
187 metabolite quantification was less than 20%, and average metabolites were only reported where at
188 least 50% of single-subject measurements met this criterion.

189

190

191 *2.4 Statistics*

192 Cohort characteristics of age, disease duration, EDSS and minimum age of lesions were compared
193 using unpaired t-tests; sex and ethnicity were compared using chi-square with Yate's correction.

194 Paired t-tests were used to compare mean T2-water estimates and measures of spectral quality. All
195 subsequent group-level statistics were computed using permutation testing in FSL's PALM with
196 10,000 permutations (Alberton et al., 2020; Jenkinson et al., 2012; Winkler et al., 2016). Unpaired
197 two-sample t-tests were used to compare lesions and areas of NAWM across groups (hypotheses 1

198 and 2). One-sample t-tests were performed to test individual lesion and NAWM metabolite
199 concentration differences within disease groups (hypotheses 2 and 3). We ran statistical tests for
200 metabolite comparisons in three batches (the fewest number that data structure and test
201 methodology would allow) to allow for family wise error rate correction. The three batches were:
202 unpaired t-tests for MS and AQP4Ab-NMOSD comparisons, one-sample t-test for AQP4Ab-NMOSD
203 lesion versus NAWM differences and one-sample t-tests for MS lesion versus NAWM differences. In
204 order to test our directionally specific hypotheses, all *a priori* group-level t-tests were one-tailed.
205 Post-hoc two-tailed t-tests, as detailed in the results, were also performed in FSL PALM.

206

207 Tests of correlation were limited to common associations described in the literature, namely
208 disability's association with NAA:tCr (normal appearing brain tissue & lesions) (Khan et al., 2016;
209 Mainero et al., 2001), Ins:NAA (normal appearing white and grey matter) (Llufriu et al., 2014; Miller
210 DH, 2014) and GABA (normal appearing grey matter) (Cawley et al., 2015), and disease duration's
211 association with Ins, NAA, Cr, tCr and tCho (normal appearing brain tissue) (Kirov et al., 2013).
212 Correlations were evaluated visually and with R-square (R^2), however due to low numbers of
213 participants and the relatively large number of tests, p-values were not calculated except for post-
214 hoc testing of Pearson's correlation coefficient in the case of ml:NAA vs EDSS (See supplemental
215 figure 2). Pearson's correlations performed in R (R Core Team, 2017; Wickham, 2016).

216 3. Results

217 Patient characteristics are listed in Table 1. Three of the four AQP4Ab-NMOSD participants were
218 Afro-Caribbean and one was Asian, in line with the non-Caucasian predominance in this disease. One
219 MS participant was Afro-Caribbean, the remainder were Caucasian. All lesions studied were hyper-
220 intense on the FLAIR image and hypo-intense on the T1 weighted image. The minimum age of the
221 brain lesions ranged from 132 days to 9 years.

222

223

224 *3.1 MRS quality metrics*

225 We first wanted to ensure that there were no systematic differences in the quality of the LCModel fit
226 between the NAWM and lesion VOIs. Reported CRLB estimates were generally low in all cases.
227 However, in our MS sample Ala, Asc, Asp, Lac, PCho and Scyllo did not meet our CRLB criterion and
228 were therefore excluded from further analysis. Likewise, for MS, 5 lesion and 5 NAWM measures
229 were excluded from GABA analysis, 1 lesion and 4 NAWM measures from Gln, 1 lesion and 1 NAWM
230 measure from Glc+Tau, 2 lesion and 1 NAWM measure from PE, and 1 NAWM measure from Tau.
231 For AQP4Ab-NMOSD data, Ala, Asp, Lac, PCho and Scyllo did not meet the CRLB requirements and
232 were excluded. Likewise, 1 lesion measure was excluded from GABA analysis and 2 lesion and 2
233 NAWM measure from Asc. For the remaining metabolites we then wished to ensure that there was
234 no significant difference in the quality of fit between NAWM and lesion groups. Statistical analyses
235 demonstrated no differences, when tests were corrected for multiple comparisons (paired t-test p-
236 values, $\alpha = 0.05$, Bonferroni threshold = $0.05/19 = 0.0026$: $0.0025 < p < 0.05$: AQP4Ab-NMOSD Gln
237 $p=0.011$, AQP4Ab-NMOSD Asc 0.015, MS Glu 0.049; $p > 0.05$ for all other metabolites; see Table 3).

238 *3.2 T2 differences between lesions and normal-appearing*

239 *tissue are relevant for metabolite quantification*

240 There was no difference between the LCModel estimated line-widths (Full Width Half Maximum,
241 FWHM) and Signal-to-Noise ratios (S/N) of the spectra from the NAWM and lesioned tissue (table 2;
242 S/N: 25.7 ± 5.6 vs 28.3 ± 4 , $p=0.10$; FWHM: 0.03 ± 0 vs 0.03 ± 0 , $p=0.96$). However, estimated T2-water
243 relaxation time was higher in both MS and AQP4Ab-NMOSD lesion voxels than for NAWM voxels,
244 reflecting the higher free-water content in this tissue (43.7 ± 2.8 vs 39.9 ± 2.6 , $p=0.0001$). We

245 therefore went on to quantify neurochemicals in MS and AQP4Ab-NMOSD lesions and NAWM
246 spectra using T2-corrected spectra.

247

248

249 *3.3 Differences in neurochemical profiles between NAWM and* 250 *lesions in MS*

251 Next, we investigated neurochemical differences between lesions and NAWM. All *a priori* group-
252 level t-tests were unidirectional (one-tailed) in accordance with our hypotheses. In the MS group
253 absolute tNAA was lower in lesions compared to NAWM ([NAWM tNAA] – [lesion tNAA]: 1.21 ± 1.31
254 (mean \pm SD); one-sample $t(10)=2.91$, $p=0.020$). Given that, as discussed above, tNAA is comprised of
255 two metabolites with very different physiological roles, we therefore wanted to investigate whether
256 this difference in tNAA was driven by a decrease in NAAG, or NAA, or both. NAAG was lower in
257 lesions than in NAWM ([NAWM NAAG] – [lesion NAAG]: 0.46 ± 0.57 ; one-sample $t(10)=2.52$,
258 $p=0.048$), but only a trend towards lower values in lesions was found for NAA ([NAWM NAA] –
259 [lesion NAA]: 0.75 ± 1.13 ; one-sample $t(10)=2.10$, $p=0.076$) (Figures 2 & 3 and Table 3A). Again,
260 Inositol was greater in MS lesions than in NAWM ([lesions Ins] – [NAWM Ins]: 0.82 ± 0.99 ; $t(10)=2.62$;
261 $p=0.036$; Figure 3 & Table 3A).

262

263

264 *3.4 No difference in neurochemical profiles between NAWM* 265 *and lesions in AQP4Ab-NMOSD*

266 Again with one-tailed t-tests of NAWM and lesion metabolite concentration differences, within the
267 AQP4Ab-NMOSD patients, we found no difference in tNAA (note that this is $n=4$; [NAWM tNAA]-

268 [lesion tNAA]: 1.48 ± 2.06 (mean \pm sd); one-sample $t(3)=1.24$, $p=0.375$). When the two metabolites
269 that contribute to tNAA were investigated separately, neither NAA nor NAAG differed between
270 NAWM and lesions, despite NAAG being visibly greater in NAWM ([NAWM NAA]-[lesion NAA]: 0.79
271 ± 1.84 ; one-sample $t(3)=0.74$, $p=0.625$; [NAWM NAAG]-[lesion NAAG]: 0.69 ± 0.3 ; one-sample
272 $t(3)=3.96$, $p=0.125$) (See Figure 3). Inositol did not differ between NAWM and lesioned tissue
273 ([NAWM Ins] - [lesion Ins]: -0.63 ± 0.78 ; one-sample $t(3)=-1.40$, $p=1.000$) (see Figure 3 & Table 3B).
274 There were thus no differences in either tNAA, NAA, NAAG or Inositol between the lesion and
275 NAWM groups in AQP4Ab-NMOSD.

276

277

278 *3.5 Greater tNAA in NAWM in MS compared with AQP4Ab-*

279 *NMOSD*

280 We then wanted to compare neurochemical concentrations between MS and AQP4Ab-NMOSD.
281 Unpaired one-tailed two-sample t-tests were used. NAWM concentrations of NAA, NAAG and tNAA
282 were not lower in MS NAWM (AQP4Ab-NMOSD>MS NAWM NAA: $8.69 \pm 0.7 > 9.69 \pm 0.9$; two-sample
283 $t(13)=-1.7912$; AQP4Ab-NMOSD>MS NAWM NAAG: $2.19 \pm 0.3 > 2.55 \pm 0.9$; two-sample $t(13)=-0.7316$;
284 AQP4Ab-NMOSD>MS NAWM tNAA: $10.89 \pm 0.4 > 12.24 \pm 0.9$; two-sample $t(13)=-2.7458$; all p-values
285 >1.000). However, on visual inspection of the data, tNAA appeared to be greater in MS compared to
286 AQP4Ab-NMOSD NAWM. A post-hoc two-tailed unpaired t-test (uncorrected for multiple
287 comparisons) was significant (MS>AQP4Ab-NMOSD tNAA: $12.24 \pm 0.9 > 10.89 \pm 0.4$; $t(13)=2.75$,
288 $p=0.0183$).

289 Inositol was not greater in MS versus AQP4AB-NMOSD lesions (MS>AQP4Ab-NMOSD Ins: $8.1 \pm 1.4 >$
290 7.86 ± 1.3 ; two-sample $t(13)=0.268$, $p=1.000$) (Figure 3).

291 For completeness, we tested for a significant interaction of site (NAWM / lesion) by group (MS /
292 AQP4Ab-NMOSD) for NAA, NAAG, tNAA and Ins (including our *a priori* expectations regarding the
293 direction of difference) and this was non-significant for all comparisons (all $p > 0.9$).

294 ***3.6 Ins:NAA correlates with clinical score in AQP4Ab-NMOSD***

295 Finally, we wished to investigate whether there were any relationships between our metabolites of
296 interest and disease scores (See supplemental figure 2). Of relationships previously reported in the
297 literature, we demonstrated a striking linear correlation between NAWM Ins:NAA and EDSS for *both*
298 MS and AQP4Ab-NMOSD (MS: $R^2=0.22$, AQP4Ab-NMOSD: $R^2=0.91$, respectively; $R^2=0.30$ combined).
299 Post-hoc tests, uncorrected for multiple comparisons, showed that this was significant for the
300 pooled data (AQP4Ab-NMOSD + MS NAWM Ins:NAA \propto EDSS: $r(13)=0.55$, $p=0.033$) and for AQP4Ab-
301 NMOSD alone (AQP4Ab-NMOSD NAWM Ins:NAA \propto EDSS; $r(2)=0.95$; $p=0.048$), but not for MS alone
302 (MS NAWM Ins:NAA \propto EDSS: $r(9)=0.47$, $p=0.141$).

303 We additionally explored the relationship between Ins:NAA, disease group (MS / AQP4Ab-NMOSD)
304 and MRS site (lesion / NAWM) with post-hoc two-tailed t-tests (uncorrected for multiple
305 comparisons). We found that lesion Ins:NAA was significantly greater than NAWM Ins:NAA in MS
306 (MS lesion Ins:NAA vs control Ins:NAA: 0.76 ± 0.12 vs 0.91 ± 0.10 ; one-sample $t(10)=5.42$) but for all
307 other comparisons was non-significant.

308 **4. Discussion**

309 This study was performed in order to investigate the patterns of neurochemical changes in lesioned
310 tissue and in normal appearing white matter in multiple sclerosis (MS) and aquaporin-4 antibody
311 positive neuromyelitis optica spectrum disorder (AQP4Ab-NMOSD). To do this, we acquired
312 Magnetic Resonance Spectroscopy (MRS) data using an optimised sequence for seven tesla (7T) MRI.

313 We demonstrated significant differences in water T2 relaxation times between lesions and NAWM,
314 which we corrected for in subsequent analyses.

315

316 Using this corrected data, as expected, Total NAA (tNAA) was lower in MS lesions compared to MS
317 NAWM and Inositol was greater in MS lesions compared to MS NAWM, in line with historical MRS
318 studies that attribute these features respectively to the axonal loss and gliosis seen in MS lesions
319 (Arnold et al., 1992; Davie et al., 1994). We demonstrated no differences between lesion and
320 NAWM in AQP4Ab-NMOSD patients, and no differences in either NAA or Inositol between MS and
321 AQP4Ab-NMOSD lesions. We did show, however, a relationship between NAA:Ins, commonly
322 thought to be a marker of neuronal loss and gliosis, and clinical disability score in both groups
323 (Llufriu et al., 2014; Miller DH, 2014).

324 *4.1 Optimised MRS allowed us to address important confounds*

325 A number of parameters were optimised to acquire our 7T MRS spectra. The STEAM sequence was
326 chosen despite the loss of half of the available signal to minimize relaxation effects at a short echo
327 time. Transverse relaxation differences between lesion sites and NAWM at longer TEs have the
328 potential to confound the quantification of metabolite concentrations.

329

330 The achieved spectral quality (high spectral resolution, SNR, efficient water suppression, and a
331 distortionless baseline) allowed reliable quantification of 17-18 metabolites in periventricular white
332 matter (VOI = 15 x 15 x 15 ml) using LCModel analysis. T2-water relaxation times were significantly
333 higher in lesioned tissue as confirmed in previous studies (Laule et al., 2007b, 2007a), and quantifies
334 what one would expect given their features on T2-weighted images where lesions are identified
335 clinically by their bright (hyperintense) appearance.

336

337 We avoided over-reliance on metabolite ratios (e.g. tNAA:tCr) and corrected for multiple T2-
338 relaxation components. Both are of particular importance within neuroinflammatory conditions, the
339 former because a parallel loss of tCr in damaged tissue may conceal tNAA loss when expressed as
340 tNAA:tCr (Davies et al., 1995) and the latter because brain lesions often have a higher percentage of
341 water compared to surrounding tissue. Accurate absolute quantification of metabolites, powerful in
342 their own right, also allow for meaningful interpretation of metabolite ratios where applied.

343 *4.2 Lower NAA-G in MS lesions than in NAWM*

344 A decrease in NAA in MS lesions has long been described (Arnold et al., 1992; Davie et al., 1994).
345 However, a number of questions have remained to be conclusively answered about this finding,
346 which we are able address here. Firstly, as discussed above, accounting for T2 relaxation times
347 allows us to be sure that this is a true reflection of the underlying pathology and not an artefact of
348 the acquisition protocols.

349

350 Secondly, our optimised MRS allowed us to accurately separate tNAA into its constituent parts: NAA
351 and NAA-G. Although these two neurochemicals have similar molecular structures, meaning that
352 they are hard to distinguish using MRS, they have distinct functional roles. The role of NAA is not
353 entirely clear, but is a reflection of neuronal mitochondrial function, and has been hypothesised to
354 have a role in myelination (Birken and Oldendorf, 1989; Moffett et al., 2007). NAAG, the most
355 abundant peptide in the central nervous system, is found in both neurones and glia, acts as both a
356 neurotransmitter and a glutamate reservoir, and is higher in white matter compared to grey matter
357 (Chiew et al., 2018; Neale et al., 2000). NAAG in MS NAWM may reflect glial cell number and may
358 also have a neuroprotective role via its ability to activate the metabotropic glutamate receptor,
359 mGluR. As discussed above, it is possible that higher NAWM versus lesion tNAA is a reflection of *up-*
360 *regulated* NAAG in NAWM as well as loss of NAAG (and NAA) in lesions and could be interpreted as a
361 response to disease activity (Vrenken et al., 2005).

362 ***4.3 No differences in NAA or Inositol between lesions and*** 363 ***NAWM in AQP4Ab-NMOSD patients***

364 Within our four AQP4Ab-NMOSD patients, no differences were found between lesion and control
365 sites for NAA, tNAA or Ins. Interpretation of these results is of course difficult given the small
366 number of AQP4Ab-NMOSD patients in this study. However, to our knowledge there is only one
367 other study describing AQP4Ab-NMOSD MRS findings in central nervous system lesions and that
368 study focuses solely on the spinal cord (Cicarelli et al., 2013). Ciccarelli and colleagues found lower
369 Inositol in AQP4Ab-NMOSD lesions relative to MS lesions which in turn had lower concentrations
370 than healthy controls, and they hypothesised that this demonstrated astrocyte loss. There are no
371 brain studies of AQP4Ab-NMOSD lesions versus NAWM for appropriate comparison and assumptions
372 about AQP4Ab-NMOSD brain lesion metabolites from spinal cord data should be made with caution,
373 especially given that no AQP4Ab-NMOSD control site was sampled in Ciccarelli's study and no
374 healthy control group was sampled in ours. It must also be noted that both ours and Ciccarelli's
375 studies have low numbers of AQP4Ab-NMOSD participants (4 and 5, respectively).

376 ***4.4 tNAA higher in NAWM in MS than AQP4Ab-NMOSD*** 377 ***patients***

378 There were no differences for *a priori* tests comparing AQP4Ab-NMOSD and MS lesion and control
379 sites. However a post-hoc non-parametric t-test performed after unexpected differences were noted
380 in plotted data revealed tNAA to be greater in MS compared to AQP4Ab-NMOSD NAWM, contrary to
381 our hypothesis. Low tNAA in MS in contrast to AQP4Ab-NMOSD NAWM is usually offered as support
382 for the hypothesis that MS pathogenesis involves a chronic extra-lesional neurodegenerative
383 processes that is absent from AQP4Ab-NMOSD pathology (Huda et al., 2019). However, this finding
384 has been challenged by Vrenken et al who found that the only significant difference between
385 healthy controls and MS NAWM was a difference in NAAG (and not tNAA or NAA), and that NAAG
386 wasn't *lower* in NAWM of MS patients but was instead *raised* compared to controls (Vrenken et al.,
387 2005). This explanation better fits with our data and is supported by a recent study of healthy

388 participants, in whom absolute tNAA NAWM concentrations are lower than in MS NAWM here, and
389 more in line with our AQP4Ab-NMOSD tNAA NAWM values (~8.7 mmol/L for 20-60 year olds) (Ding
390 et al., 2016).

391

392 Contrary to our initial hypothesis, we did not find greater Inositol in MS lesions compared with
393 AQP4Ab-NMOSD lesions. It is not clear why this might be, and interpreting a null result in an n of 4
394 should be treated with caution, but it may be that this reflects the known pathology of some chronic
395 AQP4Ab-NMOSD lesions where a period of gliosis supervenes over the astrocytic death of the acute
396 lesion stage (Lucchinetti et al., 2014). MRS Inositol has been previously suggested as a potential
397 differentiator for MS and AQP4Ab-NMOSD because astrocytes are reduced pathologically in
398 AQP4Ab-NMOSD and increased in MS (Geraldes et al., 2018), but this assumption rests on data from
399 the only study besides ours to have performed MRS in AQP4Ab-NMOSD lesions, and that study was
400 in spinal cord lesions not brain lesions (Ciccarelli et al., 2013).

401

402 One explanation for the different Inositol concentrations between Ciccarelli's study and the results
403 presented here is that we have studied lesions of different ages: our study examined older lesions
404 more likely to be in the gliotic stage (4-24 months vs 43-116 months). It is also possible that spinal
405 cord lesions are in general more destructive than brain lesions, leading to astrocyte loss, whereas
406 brain lesions are commonly more subtle, non-demyelinating, non-necrosing and sometimes
407 reversible (indeed, historically, brain lesions were thought to be atypical of AQP4Ab-
408 NMOSD)(Lucchinetti et al., 2014; Pittock et al., 2006). Finally, AQP4Ab-NMOSD lesions in the cord
409 are centred on grey matter, while those in the brain are found primarily white matter, which may be
410 an important factor in gliosis (Lucchinetti et al., 2014).

411 *4.5 Ins:NAA correlates with disability*

412 We also found a correlation between Ins:NAA and disability (as assessed by EDSS), which was
413 significant on post-hoc testing for both disease groups combined and for AQP4Ab-NMOSD alone
414 (Supplemental Figure 2). This correlation suggests that higher Ins:NAA relates to worse clinical
415 score. Consistent with this finding, NAWM Ins:NAA has been shown in one study of MS patients to
416 predict subsequent clinical disability, with higher Ins:NAA predicting greater EDSS score increase
417 (Llufriu et al., 2014). It has been hypothesised that the CNS immune process in MS leads to an
418 increase of inositol and the neurodegeneration causing long-term disability results in reduced NAA,
419 hence Ins:NAA is greater in more destructive and longer-lasting disease (Llufriu et al., 2014; Miller
420 DH, 2014). We found a similar association of Ins:NAA and EDSS across the whole group, but this was
421 primarily driven by the strong relationship between Ins:NAA and EDSS in AQP4Ab-NMOSD NAWM
422 (albeit in n=4). This is surprising, as the received wisdom is that AQP4Ab-NMOSD NAWM is relatively
423 free from damage, at least outside the optic nerve and cortico-spinal tracts (Aboul-Enein et al., 2010;
424 Bichueti et al., 2008; De Seze et al., 2010; Matthews et al., 2015). However, even if only small
425 differences in NAWM NAA and Inositol occur, provided the differences decrease in magnitude with
426 increasing EDSS, Ins:NAA will increase proportionally with EDSS. In our four AQP4Ab-NMOSD
427 patients we found no-change or a slight increase in NAA with EDSS (i.e. no evidence of neuronal loss
428 in NAWM in line with existing literature), along with a proportionally greater increase in Ins.

429 *4.6 Limitations*

430 Our study sought to compare AQP4Ab-NMOSD and MS neurochemicals using MRS, but has some
431 limitations. Firstly, no healthy control population was used as a comparator for NAWM brain voxels.
432 Instead, patients' own NAWM was used as a control site to compare with lesion sites. As such, it is
433 impossible to be sure whether the differences described above are driven by pathological increases
434 or decrease or both, except through comparison with previously published values, which have
435 invariably used different techniques and assessed different anatomical locations. It is thus possible

436 that a structured difference in sampling location by disease type has biased the findings, given that
437 we know MRS measures differ slightly across different lobes of the brain (Ding et al., 2016). Further,
438 there is MRS and MRI diffusion imaging evidence of mirror changes (tNAA:tCr and apparent diffusion
439 coefficient, respectively) that occur contralaterally to sites of lesions in multiple sclerosis (Stefano et
440 al., 1999; Werring et al., 2000). These could conceivably reduce the magnitude of lesion versus
441 NAWM differences investigated here, or hide them altogether. Secondly, lesions were all at least 3
442 months old (i.e. chronic) at the time of assessment. This makes our results comparable with most
443 but not all previous MS MRS lesion studies but means little insight can be gained into changes with
444 lesion progression. Finally, AQP4Ab-NMOSD disproportionately affects Afro-Caribbean individuals,
445 whereas MS is commonly considered a disease of Caucasians. As such, matching ethnicity is difficult
446 for studies comparing these two patient groups. It is not clear what effect, if any, this would have on
447 the data.

448 5. Conclusion

449 Here we present results from an early, comprehensive metabolite profile of MS and AQP4Ab-
450 NMOSD chronic lesions and normal appearing white matter acquired using magnetic resonance
451 spectroscopy (MRS) at 7T. The study utilises an optimised methodology, including correction for
452 multiple T2-water relaxation times, and our results are broadly in line with previous MRS studies in
453 neurodegenerative conditions, but serve to highlight some under-explored subtleties in MRS profiles,
454 such as the absence of Inositol concentration differences in AQP4Ab-NMOSD brain lesions versus
455 NAWM and the important influence of NAAG differences between lesions and normal appearing
456 white matter. We hope that the technique described here will be highly relevant for future 7T MRS
457 studies of this sort.

458 Acknowledgements

459 This work was funded by the MS Society (grant number 858/07) and the Guthy Jackson Charitable
460 Foundation. The research was additionally supported by the National Institute for Health Research
461 (NIHR) Oxford Biomedical Research Centre, and the NIHR Oxford Health Biomedical Research
462 Centre. The Wellcome Centre for Integrative Neuroimaging is supported by core funding from the
463 Wellcome Trust (203139/Z/16/Z). GT holds an Institutional Strategic Support Fund (ISSF) Fellowship
464 funded by the Wellcome trust and received funding from the Economic and Social Research Council's
465 (ESRC's) postdoctoral fellowship programme prior to the current post. CJS holds a Sir Henry Dale
466 Fellowship, funded by the Wellcome Trust and the Royal Society (102584/Z/13/Z).

467 Data Statement

468 Due the clinically sensitive nature of the data it is have not been made freely available. However,
469 should you or your organisation have an interest in acquiring this data for the purpose of furthering
470 the understanding of multiple sclerosis and neuromyelitis optica, please get in touch with the
471 corresponding author.

472

473 Declaration of Interest

474 GT reported no declarations of interest.

475 YK reported no declarations of interest.

476 RM reported no declarations of interest.

477 SM reported receiving travel grants from Biogen, Novartis, Bayer, Merck & Co, Roche, and Almirall
478 and honorarium from Biogen for advisory work.

479 AW reported no declarations of interest.

480 AC reported no declarations of interest.

481 RE reported no declarations of interest.

482 GDL is supported by the NIHR Biomedical Research Centre (BRC), Oxford and has research funding
483 from the Oxford BRC, MRC(UK), UK MS Society, and National Health and Medical Research
484 (Australia). GD has received travel expenses from Bayer Schering, Biogen Idec, Genzyme, Merck
485 Serono, Novartis, American Academy of Neurology, and MS Academy, and honoraria as an invited
486 speaker for Novartis, American Academy of Neurology, and MS Academy.
487 AW reported no declarations of interest.
488 MC reported no declarations of interest.
489 IT reported no declarations of interest.
490 JP reported no declarations of interest.
491 CS reported no declarations of interest.
492 UE reported no declarations of interest.

493

494 References


- 495 Aboul-Enein, F., Krššák, M., Höftberger, R., Prayer, D., Kristoferitsch, W., 2010. Diffuse White Matter
496 Damage Is Absent in Neuromyelitis Optica. *Am. J. Neuroradiol.* 31, 76–79.
497 <https://doi.org/10.3174/ajnr.A1791>
- 498 Alberton, B.A.V., Nichols, T.E., Gamba, H.R., Winkler, A.M., 2020. Multiple testing correction over
499 contrasts for brain imaging. *NeuroImage* 216, 116760.
500 <https://doi.org/10.1016/j.neuroimage.2020.116760>
- 501 Arnold, D.L., Matthews, P.M., Francis, G.S., O'Connor, J., Antel, J.P., 1992. Proton magnetic
502 resonance spectroscopic imaging for metabolic characterization of demyelinating plaques.
503 *Ann. Neurol.* 31, 235–241. <https://doi.org/10.1002/ana.410310302>
- 504 Baslow, M.H., 2000. Functions of N-Acetyl-L-Aspartate and N-Acetyl-L-Aspartylglutamate in the
505 Vertebrate Brain. *J. Neurochem.* 75, 453–459. <https://doi.org/10.1046/j.1471-4159.2000.0750453.x>
- 507 Bichuetti, D.B., Rivero, R.L.M., Oliveira, E.M.L., Oliveira, D.M., Amorin de Souza, N., Nogueira, R.G.,
508 Abdala, N., Gabbai, A., 2008. White matter spectroscopy in neuromyelitis optica: A case
509 control study. *J. Neurol.* 255, 1895–1899. <https://doi.org/10.1007/s00415-009-0940-0>
- 510 Birken, D.L., Oldendorf, W.H., 1989. N-Acetyl-L-Aspartic acid: A literature review of a compound
511 prominent in 1H-NMR spectroscopic studies of brain. *Neurosci. Biobehav. Rev.* 13, 23–31.
512 [https://doi.org/10.1016/S0149-7634\(89\)80048-X](https://doi.org/10.1016/S0149-7634(89)80048-X)
- 513 Brex, P., Parker, G., Leary, S., Molyneux, P., Barker, G., Davie, C., Thompson, A., Miller, D., 2000.
514 Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on
515 T1 weighted images, T1 relaxation times, and metabolite concentrations. *J. Neurol.*
516 *Neurosurg. Psychiatry* 68, 627–632. <https://doi.org/10.1136/jnnp.68.5.627>

- 517 Cawley, N., Solanky, B.S., Muhlert, N., Tur, C., Edden, R.A.E., Wheeler-Kingshott, C.A.M., Miller, D.H.,
518 Thompson, A.J., Ciccarelli, O., 2015. Reduced gamma-aminobutyric acid concentration is
519 associated with physical disability in progressive multiple sclerosis. *Brain J. Neurol.* 138,
520 2584–2595. <https://doi.org/10.1093/brain/awv209>
- 521 Chiew, M., Jiang, W., Burns, B., Larson, P., Steel, A., Jezzard, P., Thomas, M.A., Emir, U.E., 2018.
522 Density-weighted concentric rings k-space trajectory for 1H magnetic resonance
523 spectroscopic imaging at 7 T. *NMR Biomed.* 31, e3838. <https://doi.org/10.1002/nbm.3838>
- 524 Ciccarelli, O., Thomas, D.L., De Vita, E., Wheeler-Kingshott, C.A.M., Kachramanoglou, C., Kapoor, R.,
525 Leary, S., Matthews, L., Palace, J., Chard, D., Miller, D.H., Toosy, A.T., Thompson, A.J., 2013.
526 Low Myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica:
527 Astrocytic Damage in NMO. *Ann. Neurol.* n/a-n/a. <https://doi.org/10.1002/ana.23909>
- 528 Davie, C.A., Hawkins, C.P., Barker, G.J., Brennan, A., Tofts, P.S., Miller, D.H., McDonald, W.I., 1994.
529 Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. *Brain* 117,
530 49–58. <https://doi.org/10.1093/brain/117.1.49>
- 531 Davies, S.E., Newcombe, J., Williams, S.R., McDonald, W.I., Clark, J.B., 1995. High resolution proton
532 NMR spectroscopy of multiple sclerosis lesions. *J. Neurochem.* 64, 742–748.
- 533 De Seze, J., Blanc, F., Kremer, S., Collongues, N., Fleury, M., Marcel, C., Namer, I.-J., 2010. Magnetic
534 resonance spectroscopy evaluation in patients with neuromyelitis optica. *J. Neurol.*
535 *Neurosurg. Psychiatry* 81, 409–411. <https://doi.org/10.1136/jnnp.2008.168070>
- 536 De Stefano, N., Filippi, M., Miller, D., Pouwels, P.J., Rovira, A., Gass, A., Enzinger, C., Matthews, P.M.,
537 Arnold, D.L., 2007. Guidelines for using proton MR spectroscopy in multicenter clinical MS
538 studies. *Neurology* 69, 1942–1952. <https://doi.org/10.1212/01.wnl.0000291557.62706.d3>
- 539 Ding, X.-Q., Maudsley, A.A., Sabati, M., Sheriff, S., Schmitz, B., Schütze, M., Bronzlik, P., Kahl, K.G.,
540 Lanfermann, H., 2016. Physiological neuronal decline in healthy aging human brain — An in
541 vivo study with MRI and short echo-time whole-brain 1H MR spectroscopic imaging.
542 *NeuroImage* 137, 45–51. <https://doi.org/10.1016/j.neuroimage.2016.05.014>
- 543 Emir, U.E., Auerbach, E.J., Moortele, P.-F.V.D., Marjańska, M., Uğurbil, K., Terpstra, M., Tkáč, I., Öz,
544 G., 2012. Regional neurochemical profiles in the human brain measured by 1H MRS at 7 T
545 using local B1 shimming. *NMR Biomed.* 25, 152–160. <https://doi.org/10.1002/nbm.1727>
- 546 Fernando, K.T.M., McLean, M.A., Chard, D.T., MacManus, D.G., Dalton, C.M., Miskiel, K.A., Gordon,
547 R.M., Plant, G.T., Thompson, A.J., Miller, D.H., 2004. Elevated white matter myo-inositol in
548 clinically isolated syndromes suggestive of multiple sclerosis. *Brain* 127, 1361–1369.
549 <https://doi.org/10.1093/brain/awh153>
- 550 Fujihara, K., 2011. Neuromyelitis optica and astrocytic damage in its pathogenesis. *J. Neurol. Sci.*,
551 Special Section: ECF 2009 306, 183–187. <https://doi.org/10.1016/j.jns.2011.02.018>
- 552 Geraldes, R., Ciccarelli, O., Barkhof, F., De Stefano, N., Enzinger, C., Filippi, M., Hofer, M., Paul, F.,
553 Preziosa, P., Rovira, A., DeLuca, G.C., Kappos, L., Yousry, T., Fazekas, F., Frederiksen, J.,
554 Gasperini, C., Sastre-Garriga, J., Evangelou, N., Palace, J., on behalf of the MAGNIMS study
555 Group, 2018. The current role of MRI in differentiating multiple sclerosis from its imaging
556 mimics. *Nat. Rev. Neurol.* 14, 199–213. <https://doi.org/10.1038/nrneurol.2018.14>
- 557 Gruetter, R., Tkáč, I., 2000. Field mapping without reference scan using asymmetric echo-planar
558 techniques. *Magn. Reson. Med.* 43, 319–323. [https://doi.org/10.1002/\(SICI\)1522-
559 2594\(200002\)43:2<319::AID-MRM22>3.0.CO;2-1](https://doi.org/10.1002/(SICI)1522-2594(200002)43:2<319::AID-MRM22>3.0.CO;2-1)
- 560 Helms, G., 2001. Volume correction for edema in single-volume proton MR spectroscopy of contrast-
561 enhancing multiple sclerosis lesions. *Magn. Reson. Med.* 46, 256–263.
562 <https://doi.org/10.1002/mrm.1186>
- 563 Helms, G., Stawiarz, L., Kivisäkk, P., Link, H., 2000. Regression analysis of metabolite concentrations
564 estimated from localized proton MR spectra of active and chronic multiple sclerosis lesions.
565 *Magn. Reson. Med.* 43, 102–110. [https://doi.org/10.1002/\(SICI\)1522-
566 2594\(200001\)43:1<102::AID-MRM12>3.0.CO;2-I](https://doi.org/10.1002/(SICI)1522-2594(200001)43:1<102::AID-MRM12>3.0.CO;2-I)

- 567 Huda, S., Whittam, D., Bhojak, M., Chamberlain, J., Noonan, C., Jacob, A., Kneen, R., 2019.
568 Neuromyelitis optica spectrum disorders. *Clin. Med.* 19, 169–176.
569 <https://doi.org/10.7861/clinmedicine.19-2-169>
- 570 Jenkinson, M., Beckmann, C.F., Behrens, T.E.J., Woolrich, M.W., Smith, S.M., 2012. FSL. *NeuroImage*
571 62, 782–790. <https://doi.org/10.1016/j.neuroimage.2011.09.015>
- 572 Khan, O., Seraji-Bozorgzad, N., Bao, F., Razmjou, S., Caon, C., Santiago, C., Latif, Z., Aronov, R., Zak, I.,
573 Ashtamker, N., Kolodny, S., Ford, C., Sidi, Y., 2016. The Relationship Between Brain MR
574 Spectroscopy and Disability in Multiple Sclerosis: 20-Year Data from the U.S. Glatiramer
575 Acetate Extension Study. *J. Neuroimaging n/a-n/a*. <https://doi.org/10.1111/jon.12358>
- 576 Kirov, I.I., Tal, A., Babb, J.S., Herbert, J., Gonen, O., 2013. Serial proton MR spectroscopy of gray and
577 white matter in relapsing-remitting MS. *Neurology* 80, 39–46.
578 <https://doi.org/10.1212/WNL.0b013e31827b1a8c>
- 579 Kremer, S., Renard, F., Achard, S., Lana-Peixoto, M.A., Palace, J., Asgari, N., Klawiter, E.C.,
580 Tenenbaum, S.N., Banwell, B., Greenberg, B.M., Bennett, J.L., Levy, M., Villoslada, P., Saiz,
581 A., Fujihara, K., Chan, K.H., Schippling, S., Paul, F., Kim, H.J., de Seze, J., Wuerfel, J.T., Guthy-
582 Jackson Charitable Foundation (GJCF) Neuromyelitis Optica (NMO) International Clinical
583 Consortium and Biorepository, Cabre, P., Marignier, R., Tedder, T., van Pelt, D., Broadley, S.,
584 Chitnis, T., Wingerchuk, D., Pandit, L., Leite, M.I., Apiwattanakul, M., Kleiter, I.,
585 Prayoonwiwat, N., Han, M., Hellwig, K., van Herle, K., John, G., Hooper, D.C., Nakashima, I.,
586 Sato, D., Yeaman, M.R., Waubant, E., Zamvil, S., Stüve, O., Aktas, O., Smith, T.J., Jacob, A.,
587 O'Connor, K., 2015. Use of Advanced Magnetic Resonance Imaging Techniques in
588 Neuromyelitis Optica Spectrum Disorder. *JAMA Neurol.* 72, 815–822.
589 <https://doi.org/10.1001/jamaneurol.2015.0248>
- 590 Laule, C., Vavasour, I.M., Kolind, S.H., Traboulsee, A.L., Moore, G.R.W., Li, D.K.B., MacKay, A.L.,
591 2007a. Long T2 water in multiple sclerosis: What else can we learn from multi-echo T2
592 relaxation? *J. Neurol.* 254, 1579–1587. <https://doi.org/10.1007/s00415-007-0595-7>
- 593 Laule, C., Vavasour, I.M., Mädler, B., Kolind, S.H., Sirrs, S.M., Brief, E.E., Traboulsee, A.L., Moore,
594 G.R.W., Li, D.K.B., MacKay, A.L., 2007b. MR evidence of long T2 water in pathological white
595 matter. *J. Magn. Reson. Imaging* 26, 1117–1121. <https://doi.org/10.1002/jmri.21132>
- 596 Llufriu, S., Kornak, J., Ratiney, H., Oh, J., Brenneman, D., Cree, B.A., Sampat, M., Hauser, S.L., Nelson,
597 S.J., Pelletier, D., 2014. Magnetic resonance spectroscopy markers of disease progression in
598 multiple sclerosis. *JAMA Neurol.* 71, 840–847. <https://doi.org/10.1001/jamaneurol.2014.895>
- 599 Lucchinetti, C.F., Guo, Y., Popescu, B.F.Gh., Fujihara, K., Itoyama, Y., Misu, T., 2014. The Pathology of
600 an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica. *Brain Pathol.*
601 *Zurich Switz.* 24, 83–97. <https://doi.org/10.1111/bpa.12099>
- 602 Mainero, C., De Stefano, N., Iannucci, G., Sormani, M.P., Guidi, L., Federico, A., Bartolozzi, M.L.,
603 Comi, G., Filippi, M., 2001. Correlates of MS disability assessed in vivo using aggregates of
604 MR quantities. *Neurology* 56, 1331–1334. <https://doi.org/10.1212/WNL.56.10.1331>
- 605 Matthews, L., Kolind, S., Brazier, A., Leite, M.I., Brooks, J., Traboulsee, A., Jenkinson, M., Johansen-
606 Berg, H., Palace, J., 2015. Imaging Surrogates of Disease Activity in Neuromyelitis Optica
607 Allow Distinction from Multiple Sclerosis. *PLOS ONE* 10, e0137715.
608 <https://doi.org/10.1371/journal.pone.0137715>
- 609 Miller DH, 2014. Magnetic resonance spectroscopy: A possible in vivo marker of disease progression
610 for multiple sclerosis? *JAMA Neurol.* 71, 828–830.
611 <https://doi.org/10.1001/jamaneurol.2014.896>
- 612 Miller, D.H., Thompson, A.J., Filippi, M., 2003. Magnetic resonance studies of abnormalities in the
613 normal appearing white matter and grey matter in multiple sclerosis. *J. Neurol.* 250, 1407–
614 1419. <https://doi.org/10.1007/s00415-003-0243-9>
- 615 Moffett, J.R., Ross, B., Arun, P., Madhavarao, C.N., Namboodiri, A.M.A., 2007. N-Acetylaspartate in
616 the CNS: From neurodiagnostics to neurobiology. *Prog. Neurobiol.* 81, 89–131.
617 <https://doi.org/10.1016/j.pneurobio.2006.12.003>

- 618 Neale, J.H., Bzdega, T., Wroblewska, B., 2000. N-Acetylaspartylglutamate: The Most Abundant
619 Peptide Neurotransmitter in the Mammalian Central Nervous System. *J. Neurochem.* 75,
620 443–452. <https://doi.org/10.1046/j.1471-4159.2000.0750443.x>
- 621 Piechnik, S.K., Evans, J., Bary, L.H., Wise, R.G., Jezzard, P., 2009. Functional changes in CSF volume
622 estimated using measurement of water T2 relaxation. *Magn. Reson. Med.* 61, 579–586.
623 <https://doi.org/10.1002/mrm.21897>
- 624 Pittock, S.J., Lennon, V.A., Krecke, K., Wingerchuk, D.M., Lucchinetti, C.F., Weinshenker, B.G., 2006.
625 Brain Abnormalities in Neuromyelitis Optica. *Arch. Neurol.* 63, 390–396.
626 <https://doi.org/10.1001/archneur.63.3.390>
- 627 Provencher, S.W., 2001. Automatic quantitation of localized in vivo 1H spectra with LCModel. *NMR*
628 *Biomed.* 14, 260–264.
- 629 R Core Team, 2017. R: A Language and Environment for Statistical Computing. R Foundation for
630 Statistical Computing, Vienna, Austria.
- 631 Shah, S., Kellman, P., Greiser, A., Weale, P., Zuehlsdorff, S., Jerecic, R., 2009. Rapid Fieldmap
632 Estimation for Cardiac Shimming. *Proc. Intl. Soc. Mag. Reson. Med.* 566.
- 633 Stefano, N.D., Narayanan, S., Matthews, P.M., Francis, G.S., Antel, J.P., Arnold, D.L., 1999. In vivo
634 evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen
635 in multiple sclerosis. *Brain* 122, 1933–1939. <https://doi.org/10.1093/brain/122.10.1933>
- 636 Vrenken, H., Barkhof, F., Uitdehaag, B. m. j., Castelijns, J. a., Polman, C. h., Pouwels, P. j. w., 2005.
637 MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-
638 appearing white matter. *Magn. Reson. Med.* 53, 256–266.
639 <https://doi.org/10.1002/mrm.20366>
- 640 Werring, D.J., Brassat, D., Droogan, A.G., Clark, C.A., Symms, M.R., Barker, G.J., MacManus, D.G.,
641 Thompson, A.J., Miller, D.H., 2000. The pathogenesis of lesions and normal-appearing white
642 matter changes in multiple sclerosisA serial diffusion MRI study. *Brain* 123, 1667–1676.
643 <https://doi.org/10.1093/brain/123.8.1667>
- 644 Wickham, H., 2016. *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York.
- 645 Wingerchuk, D.M., Banwell, B., Bennett, J.L., Cabre, P., Carroll, W., Chitnis, T., Seze, J. de, Fujihara, K.,
646 Greenberg, B., Jacob, A., Jarius, S., Lana-Peixoto, M., Levy, M., Simon, J.H., Tenenbaum, S.,
647 Traboulsee, A.L., Waters, P., Wellik, K.E., Weinshenker, B.G., 2015. International consensus
648 diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology* 85, 177–189.
649 <https://doi.org/10.1212/WNL.0000000000001729>
- 650 Winkler, A.M., Webster, M.A., Brooks, J.C., Tracey, I., Smith, S.M., Nichols, T.E., 2016. Non-
651 parametric combination and related permutation tests for neuroimaging. *Hum. Brain Mapp.*
652 37, 1486–1511. <https://doi.org/10.1002/hbm.23115>
- 653 Zimmerman, R., Fleming, C., Lee, B., Saint-Louis, L., Deck, M., 1986. Periventricular hyperintensity as
654 seen by magnetic resonance: prevalence and significance. *Am. J. Roentgenol.* 146, 443–450.
655 <https://doi.org/10.2214/ajr.146.3.443>
656
- 657

Figure 1. Example spectra and voxel placement from single subject



A. Raw spectrum data, LCMoDel fit (for average spectra and individual metabolites), residual-error and baseline for example participant (no. 20); B. Example voxel placement (lesion outlined in black and NAWM region outlined in orange) for same subject; C. Comparison of fitted (and baseline subtracted) lesion and NAWM spectra showing differences in ml and NAA peaks, again for same subject. ppm, parts per million; Ins, *myo*-inositol; NAA, N-aspartylaspartate.

Table 1. Demographics and clinical features

	MS	NMO	All
Total n	11	4	15
Age, yrs, median (min-max)	43 (28-60)	38 (24-40)	40 (24-60)
Female, n (%)	7 (63.6)	3 (75)	10 (66.7)
Race			
Afro-caribbean (%)	1 (9.1)**	3 (75)**	4 (26.7)
Caucasian (%)	10 (90.9)**	0 (0)**	10 (66.7)
Asian (%)	0 (0)**	1 (25)**	1 (6.7)
Disease duration, yrs, mean (sd)	6.8 (5.5)	8.9 (3.2)	7.3 (5.1)
EDSS, median (min-max)	2 (0-6)	3.75 (0-6)	2.5 (0-6)
Minimum age of lesion, months, mean (sd)	36 (33.3)*	86.6 (27.1)*	49.5 (38.9)
On treatment, n (%)	8 (72.7)	4 (100)	12 (80)

* p<0.05 for MS vs NMO t-test comparison

** p<0.05 for MS vs NMO chi-square comparison


Table 2. Estimated T2-water, LCmodel estimated FWHM and SNR

	Lesion	Control	p
T2 water (ms)	43.7 (2.8)	39.9 (2.6)	0.0001
FWHM (ppm)	0.03 (0)	0.03 (0)	0.958
S/N	25.7 (5.6)	28.3 (4)	0.097

FWHM, full width half maximum

S/N, signal to noise ratio

Figure 2. Metabolite profiles for multiple sclerosis and AQP4Ab positive neuromyelitis optica



Box and whisker plots of metabolites for MS and AQP4Ab-NMOSD (NMO; min, lower-quartile, median, upper-quartile, max; outliers are >1.5 x interquartile range beyond lower or upper quartiles).

MS, multiple sclerosis; NMO, AQP4-antibody positive neuromyelitis optica; NAWM, normal appearing white matter

Table 3A. Multiple sclerosis metabolite profile (n=11)

<i>Metabolite</i>	Concentration, mmol/L				CRLB	
	<i>Lesion, mean (sd)</i>	<i>n</i>	<i>NAWM, mean (sd)</i>	<i>n</i>	<i>Lesion, mean (sd)</i>	<i>NAWM, mean (sd)</i>
Cr	3.67 (0.3)	11	3.69 (0.3)	11	8.73 (1.5)	8.55 (1.2)
PCr	4.19 (0.5)	11	4.11 (0.5)	11	8 (1.3)	8.09 (0.9)
tCr	7.85 (0.7)	11	7.79 (0.7)	11	2.27 (0.4)	2.09 (0.3)
GABA	1.27 (0.3)	6	1.32 (0.1)	6	16.5 (3.1)	16 (1.2)
Glc+Tau	1.8 (0.5)	10	1.61 (0.4)	10	12.5 (2.6)	12.7 (2)
Gln	2.1 (0.5)	10	2.06 (0.5)	7	12.4 (2.4)	13.29 (3.4)
Glu	6 (0.8)	11	6.61 (1.1)	11	4.27 (1)	3.64 (0.6)
Glx	8.04 (1.1)	11	8.34 (1.5)	11	4.45 (0.9)	4.36 (0.8)
GPC	1.68 (0.3)	11	1.63 (0.4)	11	6 (1.7)	6.36 (2.1)
tCho	1.91 (0.4)	11	1.78 (0.3)	11	4.09 (0.8)	4.18 (0.8)
GSH	1.22 (0.2)	11	1.18 (0.2)	11	10.55 (1.6)	10.91 (1.8)
Ins	8.1 (1.4)	11	7.28 (1.2)	11	2.73 (0.6)	3.09 (0.3)
NAA	8.94 (1.1)	11	9.69 (0.9)	11	2.55 (0.5)	2.36 (0.5)
NAAG	2.09 (0.6)	11	2.55 (0.9)	11	8 (2.5)	7 (2.9)
tNAA	11.03 (1.1)	11	12.24 (0.9)	11	1.91 (0.3)	1.91 (0.3)
PE	1.89 (0.4)	9	2.18 (0.4)	10	15.89 (2.7)	14.2 (2.1)
Tau	1.66 (0.4)	11	1.6 (0.4)	10	12.82 (2.6)	12.6 (2)


NAWM, normal appearing white matter; CRLB, Cramér–Rao lower bound

Table 3B. AQP4-Ab positive neuromyelitis optica spectrum disorder metabolite profile (n=4)

<i>Metabolite</i>	Concentration, mmol/L				CRLB	
	<i>Lesion, mean (sd)</i>	<i>n</i>	<i>NAWM, mean (sd)</i>	<i>n</i>	<i>Lesion, mean (sd)</i>	<i>NAWM, mean (sd)</i>
Cr	4 (0.4)	4	3.63 (0.1)	4	7.75 (0.8)	9 (1.4)
PCr	3.5 (0.7)	4	3.98 (0.3)	4	9.5 (2.7)	8.75 (1.3)
tCr	7.5 (0.7)	4	7.61 (0.3)	4	2 (0)	2.25 (0.4)
GABA	1.32 (0.2)	3	1.28 (0.3)	4	15.67 (2.6)	16.75 (2.6)
Glc+Tau	2.15 (0.4)	4	1.72 (0.1)	4	11 (1.6)	11 (2.9)
Gln	2.04 (0.3)	4	1.76 (0.2)	4	11.5 (1.1)	14.25 (1.1)
Glu	5.56 (1.2)	4	5.69 (0.7)	4	4 (0.7)	4.5 (0.9)
Glx	7.6 (1.5)	4	7.45 (0.8)	4	4 (0.7)	4.5 (0.9)
GPC	1.47 (0.3)	4	1.63 (0.2)	4	5.5 (2.1)	5.75 (1.8)
tCho	1.54 (0.3)	4	1.67 (0.2)	4	4.5 (1.1)	4.5 (0.5)
GSH	1.14 (0.1)	4	1.23 (0.2)	4	10.5 (0.9)	10.25 (1.6)
Ins	7.86 (1.3)	4	7.23 (0.8)	4	2.75 (0.4)	3 (0)
NAA	7.9 (2.2)	4	8.69 (0.7)	4	2.5 (0.5)	2.5 (0.5)
NAAG	1.5 (0.2)	4	2.19 (0.3)	4	9.25 (2.9)	7.5 (2.7)
tNAA	9.4 (2.3)	4	10.89 (0.4)	4	2 (0)	1.75 (0.4)
PE	1.95 (0.4)	4	2.11 (0.1)	4	14.25 (1.5)	13.75 (2.7)
Tau	1.84 (0.2)	4	1.72 (0.1)	4	11 (1.6)	11 (2.9)
Asc	1.87 (0.1)	2	1.53 (0.1)	2	12.5 (0.5)	16.5 (0.5)

NAWM, normal appearing white matter; CRLB, Cramér–Rao lower bound

Figure 3. Individual metabolite comparison boxplots




Boxplot representations of metabolite comparisons based on *a priori* hypotheses.


Hypotheses were unidirectional hence p-values denote significance of one-tailed t-tests. Direction of test denoted in brackets beneath p-value. MS, multiple sclerosis; NMO, neuromyelitis optica; NAWM, normal appearing white matter; L, lesion.

(Figure produced with R ggplot2 package; Wickham, 2016).



MS



NMO



Supplemental Figure 1. Voxel placement





Supplemental Figure 2. Correlations with clinical metrics

Key:

-- Multiple sclerosis

-- AQP4Ab positive neuromyelitis optica spectrum disorder



EDSS, Expanded Disability Status Scale; NAWM, normal appearing white matter